1. Scrip
  2. >>Therapy Areas
  3. >>Dermatological

BioNotebook: Tonix, XenoPort offerings; Ophthotech royalty financing; UniQure, Achaogen IPOs

 
• By Mandy Jackson

At the end of a rocky week for the stock market, including biotechnology stocks, it was not surprising to see shares of Tonix Pharmaceuticals and XenoPort lose some value on 24 January after the companies priced separate stock offerings. The declines brought their stocks in line with their offerings, which were priced below the prior day's market values.

At the end of a rocky week for the stock market, including biotechnology stocks, it was not surprising to see shares of Tonix Pharmaceuticals and XenoPort lose some value on 24 January after the companies priced separate stock offerings. The declines brought their stocks in line with their offerings, which were priced below the prior day's market values.

Emergent BioSolutions closed down 3% at $22.85 when it increased the size of its convertible senior note sale to an aggregate principal amount of $215m with a 2.875% interest rate. The Rockville, Maryland-based company previously said it would sell $200m worth of notes (scripintelligence.com,

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By Joseph Haas

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Almirall Looks To Dominate Across Derma Spectrum

 
• By Kevin Grogan

CEO Carlos Gallardo tells Scrip the Barcelona-based group has laid the foundations to advance four promising assets that have considerable potential for a variety of dermatological diseases.

More from Therapy Areas

Boehringer’s Next Generation IPF Drug Underwhelms

 
• By Andrew McConaghie

The company hoped its follow-up to blockbuster Ofev could clearly improve efficacy and safety benefits, but the full Phase III results from nerandomilast’s FIBRONEER-IPF fall short of a slam dunk.

Affimed’s ASCO ‘Hail Mary’ As Survival Chances Slim

 
• By Kevin Grogan

The German biotech has been forced into insolvency and NASDAQ suspension.

In Brief: Essence Raises Ionis Tryngolza Hypertriglyceridemia Filing Hopes

 
• By Sushmita Panda

Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.